Precision BioSciences Presents at UMDF Mitochondrial Medicine 2024, Advances PBGENE-PMM Program Towards IND and CTA Submission in 2025
Durham, N.C. - June 26, 2024: ’Precision BioSciences, Inc.’ (Nasdaq: DTIL), an advanced gene editing company leveraging its pioneering ARCUS platform for in vivo gene editing therapies, is proud to announce its latest developments at the ’United Mitochondrial Disease Foundation (UMDF)’’s ’Mitochondrial Medicine 2024 Conference’. The event, held from June 26-29 in Cleveland, Ohio, provides a unique platform to discuss critical advancements in mitochondrial disease research and therapies. Precision BioSciences’ presentation highlights the progress in its PBGENE-PMM program, with ambitions to file an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) in 2025.
Advancing Mitochondrial Medicine
At the forefront of gene editing technologies, ’Precision BioSciences’ is harnessing the potential of its proprietary ARCUS platform. This innovative tool enables the company to perform sophisticated gene edits, such as gene elimination, insertion, and excision, opening new avenues for effective treatments for various genetic disorders.
The PBGENE-PMM program, which targets mitochondrial diseases, is a testament to the company’s commitment to developing life-changing therapies. Mitochondrial diseases, often caused by genetic mutations affecting the mitochondria’s functionality, require precise and effective solutions. PBGENE-PMM aims to address these issues, paving the way for groundbreaking treatment options.
Preclinical Safety Data for HBV Therapy
In addition to the updates on PBGENE-PMM, ’Precision BioSciences’ has recently presented promising preclinical safety data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress (EASL). This data underscores the ARCUS platform’s unique capability to execute efficient, durable, and precise gene edits, essential for the targeted elimination of the Hepatitis B virus (HBV).
Highlighting the differentiated potential of ARCUS, the preclinical findings indicated that PBGENE-HBV could effectively eliminate the viral genome in infected cells, offering a potentially curative approach to HBV infections. The compelling results from these preclinical studies propel the candidate closer to clinical trials, reinforcing Precision BioSciences’ leadership in gene editing therapies.
Robust Financial Performance and Strategic Focus in 2024
Precision BioSciences also reported strong financial performance for the first quarter ending March 31, 2024. As detailed in their recent business update, the company has maintained a robust financial position, which is crucial as it continues to make strides in its research and development programs.
In 2024, the company’s strategic focus remains on the effective execution of its wholly-owned HBV and PMM programs. The ongoing advancements and financial stability underscore ’Precision BioSciences steadfast commitment to delivering innovative gene editing therapies.
Looking Ahead
As Precision BioSciences showcases its pioneering work at UMDF Mitochondrial Medicine 2024, the company is positioned at the cutting edge of genetic therapy innovations. The progress of the PBGENE-PMM program towards an IND and CTA submission in 2025, along with the advancements demonstrated in the PBGENE-HBV program, reflect the transformative impact of the ARCUS platform in addressing some of the most challenging genetic diseases.
With a strong foundation and clear strategic direction, ’Precision BioSciences’ is well-prepared to continue leading the way in developing therapies that have the potential to change the lives of patients worldwide.
Comments